MAPS Awards Grant for Pilot MDMA-assisted Massed Exposure Therapy Trial
August 27, 2024 07:00 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
MAPS, which has incubated and funded cutting-edge psychedelic research for decades, is continuing to advance our understanding of psychedelic-assisted therapiesThis study is one of the first trials...
MAPS Statement on FDA Complete Response Letter for MDMA-Assisted Therapy for PTSD New Drug Application
August 09, 2024 21:33 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
MAPS remains confident in its goal of making access to MDMA-assisted therapy for PTSD safe and legal SAN JOSE, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for...
Three Pivotal Drug Policy Organizations Hold Media Briefing/Q&A on DEA Rescheduling of Cannabis
May 01, 2024 17:54 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
WASHINGTON, May 01, 2024 (GLOBE NEWSWIRE) -- What: The Multidisciplinary Association for Psychedelic Studies (MAPS), The Marijuana Policy Project (MPP), and the National Organization for the...
MAPS Provides Psychedelic Crisis Assessment and Intervention Training to Denver’s First Responders
March 11, 2024 11:50 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
MAPS uses its over 30 years of experience in the psychedelic space to offer a first-of-its-kind gold-standard training program.
MAPS Announces Celestial Plans for Its 38th Anniversary
March 07, 2024 12:34 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
MAPS, which celebrates its 38th anniversary on April 8, will celebrate with a total solar eclipse at the Texas Eclipse 2024 festival in Texas
Psychedelic Science 2025 – the Fifth and Largest Psychedelic Conference in History – Announced for June 16-20 2025 in Denver, Colorado
February 13, 2024 13:29 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
SAN JOSE, Calif. , Feb. 13, 2024 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for Psychedelic Studies (MAPS) has announced that the Psychedelic Science 2025 Conference will convene in the...
MAPS Congratulates Lykos Therapeutics on Acceptance of New Drug Application for MDMA-Assisted Therapy for PTSD
February 09, 2024 19:30 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
The FDA has accepted Lykos Therapeutics' New Drug Application, supported by two decades of research incubated by MAPS, for MDMA-assisted therapy for PTSD.
MAPS Unveils Improved Fiscal Sponsorship Program, Empowering Innovators in the Psychedelic Movement
January 16, 2024 16:27 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
To date, MAPS has supported nearly 70 organizations worldwide to advance charitable projects in the psychedelic movementCurrently, MAPS serves as a fiscal sponsor for 10 organizations in the newly...
MAPS Welcomes New Investors, Name Change for MAPS Public Benefit Corporation
January 05, 2024 08:01 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
MAPS shares ownership of Lykos with mission-aligned investors, will continue to advance psychedelic research, change drug policy, and shape culture
MAPS Celebrates Submission of New Drug Application to FDA for MDMA-Assisted Therapy for PTSD
December 13, 2023 18:16 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
The first NDA submission for any psychedelic-assisted therapy has been submitted through a 30-year effort initiated and led by the nonprofit MAPS